J&J’s hep C drug simeprevir gets inside track at the FDA

John Carroll The agency is providing a priority review for the therapy (TMC435) in combination with interferon and ribavirin, possibly speeding its way to the market. FierceBiotech ...

Biotech financier Blech gets jail time in ‘No mercy’ sentence

Ryan McBride A federal judge wants biotech investor David Blech behind bars. Blech pleaded guilty last year to trading schemes involving stocks in the biotech companies Pluristem Therapeutics ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS